Deep Brain Stimulation (DBS) Is Expected To Gain Approval For Treatment-resistant Depression.

What Is Deep Brain Stimulation (DBS) For Treatment-Resistant Depression?

Deep brain stimulation (DBS) is a neurosurgical procedure that implants electrodes in specific brain regions to regulate abnormal neural activity. It is an established treatment for Parkinson's disease and essential tremor. For treatment-resistant depression (TRD), DBS is still in the research phase, but recent regulatory and clinical milestones are accelerating its path toward approval.

Sources: Abbott's Breakthrough Device designation announcement, Mount Sinai clinical trial announcement.

Will The FDA Approve DBS For Depression By 2027?

Our forecast model assigns a 45% probability that a DBS system will receive regulatory approval or marketing authorization for treatment-resistant depression by 2027. The timeline is uncertain because the FDA requires robust efficacy data from large, sham-controlled trials, which take years to complete. However, two key developments have increased momentum:

1. Abbott's Breakthrough Device Status: Abbott's DBS system for severe depression received FDA Breakthrough Device designation, which expedites development and review. 2. Mount Sinai's 2025 Trial Launch: Mount Sinai began a clinical trial for DBS implants in depression in 2025, adding real-world evidence.

Sources: Abbott press release, Mount Sinai study registry.

What Are The Main Barriers To Approval?

3.1 Patient Selection and Surgical Risk

DBS requires invasive brain surgery, which carries risks of infection, hemorrhage, and neurological deficits. For depression, identifying the right patients is harder than for Parkinson's because depression is heterogeneous and has no clear biomarker.

3.2 Efficacy Evidence

Prior trials (e.g., BROADEN study by St. Jude Medical) failed to meet primary endpoints in sham-controlled phases. Newer adaptive systems, like Abbott's, use real-time neural feedback, but the FDA still demands proof of durable response (often defined as 50% reduction in depression scores for 6 months).

Source: BROADEN study results.

How Will DBS Fit Into Depression Treatment If Approved?

Even if approved by 2027, DBS will remain a niche therapy, not a first-line treatment. It will be reserved for patients who have failed at least 4 to 5 standard treatments (medication, psychotherapy, ECT, TMS). The high cost (estimated $100,000+ per patient) and the need for specialized surgical centers will limit adoption to academic medical centers.

What Are The Alternative Treatments For TRD In 2025?

Alternatives include esketamine (Spravato), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), and vagus nerve stimulation (VNS). These have broader approval but lower efficacy in ultra-refractory cases. DBS offers the potential for continuous, personalized modulation, which is why it remains attractive despite risks.

Frequently Asked Questions

Q1: What Is The Difference Between DBS And VNS For Depression?

DBS targets deep brain circuits (e.g., subcallosal cingulate, ventral capsule/ventral striatum) via implanted electrodes. VNS stimulates the vagus nerve in the neck, which indirectly affects mood circuits. DBS is more targeted but more invasive; VNS is less invasive but has slower onset and lower response rates in TRD.

Q2: Which Companies Are Leading DBS Development For Depression?

Abbott (with its Infinity system and Breakthrough Device status) and Medtronic (with its Percept system) are the main players. Boston Scientific is also active, but Abbott has the most explicit regulatory pathway for TRD. Mount Sinai is the primary academic partner for Abbott's trial.

Q3: If Approved In 2027, How Long Until DBS Becomes Widely Available?

After FDA approval, Medicare and private insurers need to set reimbursement codes, which typically takes 1 to 2 years. Then, neurosurgeons need specialized training. Realistic widespread availability is 2029 to 2030, and even then, only at about 20 to 30 specialized centers in the US.

Sources: FDA Breakthrough Devices Program, Mount Sinai press release, Abbott investor relations.